TherapeuticsMD Inc (TXMD) Director Brian Bernick Sells 182,800 Shares

TherapeuticsMD Inc (NASDAQ:TXMD) Director Brian Bernick sold 182,800 shares of the company’s stock in a transaction on Monday, December 3rd. The shares were sold at an average price of $5.07, for a total value of $926,796.00. Following the completion of the transaction, the director now owns 242,000 shares of the company’s stock, valued at $1,226,940. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Brian Bernick also recently made the following trade(s):

  • On Friday, November 30th, Brian Bernick sold 91,400 shares of TherapeuticsMD stock. The shares were sold at an average price of $4.96, for a total value of $453,344.00.
  • On Tuesday, November 20th, Brian Bernick sold 182,800 shares of TherapeuticsMD stock. The shares were sold at an average price of $4.74, for a total value of $866,472.00.
  • On Friday, November 9th, Brian Bernick sold 182,800 shares of TherapeuticsMD stock. The shares were sold at an average price of $4.88, for a total value of $892,064.00.
  • On Friday, October 19th, Brian Bernick sold 182,800 shares of TherapeuticsMD stock. The shares were sold at an average price of $5.56, for a total value of $1,016,368.00.
  • On Friday, October 5th, Brian Bernick sold 91,400 shares of TherapeuticsMD stock. The shares were sold at an average price of $5.93, for a total value of $542,002.00.
  • On Friday, September 28th, Brian Bernick sold 182,800 shares of TherapeuticsMD stock. The shares were sold at an average price of $6.59, for a total value of $1,204,652.00.
  • On Thursday, September 13th, Brian Bernick sold 182,800 shares of TherapeuticsMD stock. The shares were sold at an average price of $6.30, for a total value of $1,151,640.00.

NASDAQ:TXMD traded down $0.28 during trading hours on Tuesday, reaching $4.85. The company had a trading volume of 2,426,600 shares, compared to its average volume of 2,611,786. The company has a debt-to-equity ratio of 0.55, a current ratio of 7.23 and a quick ratio of 7.15. The stock has a market capitalization of $1.20 billion, a price-to-earnings ratio of -13.11 and a beta of 1.35. TherapeuticsMD Inc has a one year low of $4.30 and a one year high of $7.66.

TherapeuticsMD (NASDAQ:TXMD) last announced its earnings results on Wednesday, November 7th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.06. The company had revenue of $3.47 million for the quarter, compared to analysts’ expectations of $4.43 million. TherapeuticsMD had a negative return on equity of 102.15% and a negative net margin of 757.59%. The business’s revenue for the quarter was down 21.5% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.07) earnings per share. Research analysts expect that TherapeuticsMD Inc will post -0.58 EPS for the current fiscal year.

TXMD has been the topic of a number of analyst reports. Cantor Fitzgerald set a $26.00 price target on TherapeuticsMD and gave the company a “buy” rating in a research report on Friday, August 10th. Oppenheimer set a $14.00 price target on TherapeuticsMD and gave the company a “buy” rating in a research report on Monday, August 13th. JPMorgan Chase & Co. set a $11.00 price target on TherapeuticsMD and gave the company a “buy” rating in a research report on Wednesday, August 15th. Zacks Investment Research cut TherapeuticsMD from a “hold” rating to a “sell” rating in a research report on Friday, August 17th. Finally, BidaskClub upgraded TherapeuticsMD from a “strong sell” rating to a “sell” rating in a research report on Wednesday, August 29th. Three investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. TherapeuticsMD presently has a consensus rating of “Buy” and an average price target of $13.45.

Hedge funds have recently made changes to their positions in the company. Stevens Capital Management LP bought a new stake in shares of TherapeuticsMD during the third quarter worth $101,000. B. Riley Wealth Management Inc. bought a new stake in shares of TherapeuticsMD during the third quarter worth $102,000. Managed Account Services Inc. bought a new stake in shares of TherapeuticsMD during the third quarter worth $117,000. Twin Focus Capital Partners LLC bought a new stake in shares of TherapeuticsMD during the second quarter worth $187,000. Finally, NumerixS Investment Technologies Inc bought a new stake in shares of TherapeuticsMD during the second quarter worth $218,000. Institutional investors own 72.66% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “TherapeuticsMD Inc (TXMD) Director Brian Bernick Sells 182,800 Shares” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The correct version of this story can be accessed at https://www.com-unik.info/2018/12/04/therapeuticsmd-inc-txmd-director-brian-bernick-sells-182800-shares.html.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a women's health care product company. Its pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen.

Featured Article: What is the quiet period?

Insider Buying and Selling by Quarter for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit